Literature DB >> 9697884

Mutational analysis of the PTEN/MMAC1 gene in non-Hodgkin's lymphoma.

Y Nakahara1, H Nagai, T Kinoshita, T Uchida, S Hatano, T Murate, H Saito.   

Abstract

The PTEN/MMAC1 gene at 10q23.3, which has dual specific phosphatase activity, is a novel tumor suppressor gene candidate. Various kinds of tumors have mutations in this gene, including glioblastoma, endometrial carcinoma and prostate cancer. We examined 29 cases of primary non-Hodgkin's lymphoma (NHL) for mutations in the PTEN/MMAC1 gene. One case of diffuse large B cell lymphoma had an 11 bp deletion, but the remaining 28 cases showed no mutations in the genome. Two of these 28 cases showed missense mutations in the PTEN/MMAC1 transcripts, but no alterations in the genomic DNA. These mRNA missense variants are similar to PTEN/MMAC1 transcript aberrations which have been reported in patients with breast cancer. These findings suggest that alterations in the PTEN/MMAC1 gene play a role in the pathogenesis of NHL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9697884     DOI: 10.1038/sj.leu.2401099

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  9 in total

1.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.

Authors:  Martina Rudelius; Stefania Pittaluga; Satoshi Nishizuka; Trinh H-T Pham; Falko Fend; Elaine S Jaffe; Leticia Quintanilla-Martinez; Mark Raffeld
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

2.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

3.  Planarian PTEN homologs regulate stem cells and regeneration through TOR signaling.

Authors:  Néstor J Oviedo; Bret J Pearson; Michael Levin; Alejandro Sánchez Alvarado
Journal:  Dis Model Mech       Date:  2008-09-18       Impact factor: 5.758

4.  Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo.

Authors:  Hans-Guido Wendel; Abba Malina; Zhen Zhao; Lars Zender; Scott C Kogan; Carlos Cordon-Cardo; Jerry Pelletier; Scott W Lowe
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

5.  Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.

Authors:  Sonali M Smith; Koen van Besien; Theodore Karrison; Janet Dancey; Peter McLaughlin; Anas Younes; Scott Smith; Patrick Stiff; Eric Lester; Sanjiv Modi; L Austin Doyle; Everett E Vokes; Barbara Pro
Journal:  J Clin Oncol       Date:  2010-09-13       Impact factor: 44.544

6.  Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination.

Authors:  Akira Suzuki; Tsuneyasu Kaisho; Minako Ohishi; Manae Tsukio-Yamaguchi; Takeshi Tsubata; Pandelakis A Koni; Takehiko Sasaki; Tak Wah Mak; Toru Nakano
Journal:  J Exp Med       Date:  2003-03-03       Impact factor: 14.307

7.  Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma.

Authors:  M H Kulke; R D Odze; K S Thakore; G Thomas; H Wang; M Loda; C Eng
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

8.  miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation.

Authors:  Zhi-Jian Zou; Lei Fan; Li Wang; Ji Xu; Run Zhang; Tian Tian; Jian-Yong Li; Wei Xu
Journal:  Oncotarget       Date:  2015-01-20

Review 9.  The PTEN tumor suppressor gene and its role in lymphoma pathogenesis.

Authors:  Xiaoxiao Wang; Huiqiang Huang; Ken H Young
Journal:  Aging (Albany NY)       Date:  2015-12       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.